All In Biotech

Drug Trial Radar · NCT00788229

Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome

A Phase II, Randomized, Double-Blind, Clinical Trial to Evaluate the Efficacy and Safety of DHP-101, DHP-300, DHP-500 in Patients With Dry Eye Syndrome

Last checked: Nov 19, 2026Latest source record: Apr 2, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Nov 2008

Primary completion

Aug 2009

Study completion Aug 2009

Sponsor

Lead sponsor
Dhp Korea Co., Ltd.Industry
Sponsor type
Industry
First posted
Nov 10, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether artificial tears are safe and effective in the treatment of Dry Eye Syndrome.

Conditions

  • Dry Eye Syndromes
  • Keratoconjunctivitis Sicca

Interventions

  • AT01Drug

    eye drop for 12 weeks

  • AT02Drug

    eye drop for 12 weeks

  • AT03Drug

    eye drop for 12 weeks

  • AT04Drug

    eye drop for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Tear Break Up Time (TBUT)Time frame: 12weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Asan medical center

    Seoul, 388-1 Pungnap-2dong, Songpa-gu, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.